The Participatory Evaluation (of) Aging (with) Rapamycin (for) Longevity Study AMA

Read the Story

Show Top Comments

Hello, I been reading about this study and heard it works on all organisms so far. My question would be what’s the likely hood of this succeeding to phase 3?


Considering known side effects of mTOR inhibition, such as mouth ulcers, as observed in Joan Mannick’s Phase 2 trials with everolimus published in Sci Transl Med, is participant unblinding a concern? If so, how will treated subjects be prevented from determining whether they’re in placebo or treatment group? I feel this could be important for some more subjective outcomes, but it’s good that there are some objective outcomes being measured


How much of a spanner in your research would it be If rapamycin yielded nothing promising? Does it put us back to square one, or would it grant us greater insight on potential alternative therapies?


So this is like a phase 1 trial. The drug is important in metabolism but im not sure if your endpoints explore that. Also, ever thought about seeing if the cells can replicate more before reaching senescence or is that more telomere.


How can an immunosuppressant that’s used on transplant patients, extend life, when it’s known that immunity is a core element of health? I’m not implying that it’s not efficient longevity wise, it’s just seems a bit counterintuitive.